oxidopamine has been researched along with CKD-MBD in 1 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Egorova, LK | 1 |
1 other study available for oxidopamine and CKD-MBD
| Article | Year |
|---|---|
[The effect of L-DOPA and 6-hydroxydopamine on the intracellular cAMP level in the kidneys of rats with impaired neurotrophic support of the organs].
Topics: Adrenalectomy; Animals; Chronic Kidney Disease-Mineral and Bone Disorder; Cyclic AMP; Kidney; Levodo | 1993 |